Citation Impact
Citing Papers
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
2012 Standout
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
2008 Standout
Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist
2004 StandoutNobel
Metastasis: from dissemination to organ-specific colonization
2009 Standout
National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents
2008
Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register
2009
Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)
2008
Improving the outcome of patients with castration-resistant prostate cancer through rational drug development
2006
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis
2007
Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial
2006 Standout
Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2
2007
Psoriasis
2009 Standout
Phase II Evaluations of Cilengitide in Asymptomatic Patients with Androgen-Independent Prostate Cancer: Scientific Rationale and Study Design
2006
Integrins in cancer: biological implications and therapeutic opportunities
2009 Standout
Cancer to bone: a fatal attraction
2011 Standout
Contribution of platelets to tumour metastasis
2011 Standout
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone‐refractory prostate cancer
2007
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
2012 Standout
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
2008 Standout
Hypoxia-Induced Lysyl Oxidase Is a Critical Mediator of Bone Marrow Cell Recruitment to Form the Premetastatic Niche
2009 Standout
Cancer Metastasis: Building a Framework
2006 Standout
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
2013 Standout
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Inflammatory bowel disease: clinical aspects and established and evolving therapies
2007 Standout
Ustekinumab: Lessons Learned from Targeting Interleukin‐12/23p40 in Immune‐Mediated Diseases
2009
Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee
2004 Standout
Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial
2008
Tumor Metastasis: Molecular Insights and Evolving Paradigms
2011 Standout
Psoriasis
2021 Standout
Psoriasis: Which therapy for which patient
2018
Isolation of rare circulating tumour cells in cancer patients by microchip technology
2007 StandoutNature
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trial
2006
Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience
2007
Adalimumab for long‐term treatment of psoriatic arthritis: Forty‐eight week data from the adalimumab effectiveness in psoriatic arthritis trial
2007
Clinical management of psoriatic arthritis
2018
Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty‐four–week efficacy and safety results of a randomized, placebo‐controlled study
2009
Chronic inflammatory diseases: Do immunological patterns drive the choice of biotechnology drugs? A critical review
2014
Ankylosing spondylitis
2007 Standout
Magnetic nanoparticles in MR imaging and drug delivery
2008 Standout
Endothelin—Biology and disease
2010
Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial
2006
TNFα blockade in human diseases: An overview of efficacy and safety
2007
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
2007 Standout
Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial
2006
Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease
2007
Cancer treatment and survivorship statistics, 2012
2012 Standout
Altered bone remodeling in psoriatic arthritis
2008
Zibotentan for the treatment of castrate-resistant prostate cancer
2010
Functional Specialization of Interleukin-17 Family Members
2011 Standout
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial
2009
10 Years of GWAS Discovery: Biology, Function, and Translation
2017 Standout
Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called 'efficacy and safety' trials: a survey of power considerations
2008
The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study
2007
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register
2007
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
2010 Standout
The endothelin axis: emerging role in cancer
2003
The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder
2006
Macrophage Cytokines: Involvement in Immunity and Infectious Diseases
2014 Standout
Topological design and additive manufacturing of porous metals for bone scaffolds and orthopaedic implants: A review
2016 Standout
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
2019
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
2013 Standout
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
2011 StandoutNobel
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
2011 Standout
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
2013
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
2012 StandoutNobel
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
2017 Standout
Osteoblasts in prostate cancer metastasis to bone
2005
Drug therapies for peripheral joint disease in psoriatic arthritis: a systematic review.
2006
Click Chemistry for Drug Development and Diverse Chemical–Biology Applications
2013 Standout
Sustained Clinical Response and High Infliximab Survival in Psoriatic Arthritis Patients: A 3-year Long-Term Study
2007
A review of shape memory alloy research, applications and opportunities
2013 Standout
Dickkopf Homolog 1 Mediates Endothelin-1-Stimulated New Bone Formation
2006
Therapies for dactylitis in psoriatic arthritis. A systematic review.
2006
Psoriasis Pathogenesis and Treatment
2019 Standout
Endothelin B Receptor, a New Target in Cancer Immune Therapy
2009
Biomedical Applications of Shape Memory Alloys
2011
Prostate Cancer Clinical Trial End Points: “RECIST”ing a Step Backwards
2005
Therapies for axial disease in psoriatic arthritis. A systematic review.
2006
G Proteins in Cancer: The Prostate Cancer Paradigm
2004
A Diet Low in Red and Processed Meat Does Not Reduce Rate of Crohn’s Disease Flares
2019 Standout
Development and Evaluation of Endothelin-A Receptor (Radio)Ligands for Positron Emission Tomography
2011
Expression of endothelin-1, endothelin-A, and endothelin-B receptor in human breast cancer and correlation with long-term follow-up.
2003
Fibrosis — A Common Pathway to Organ Injury and Failure
2015 Standout
NCCN Task Force Report: Bone Health in Cancer Care
2013
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
2016 StandoutNobel
Safety and Efficacy of Adalimumab in Treatment of Patients with Psoriatic Arthritis Who Had Failed Disease Modifying Antirheumatic Drug Therapy
2008
Soft Robotic Grippers
2018 Standout
Endothelin Axis Is a Target of the Lung Metastasis Suppressor Gene RhoGDI2
2005
TNF‐mediated inflammatory disease
2007 Standout
The Association Between Measures of Progression and Survival in Castrate-Metastatic Prostate Cancer
2007
Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
2008 Standout
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis
2020 Standout
Basic Mechanisms Responsible for Osteolytic and Osteoblastic Bone Metastases
2006
Targeting Bone Metastasis in Prostate Cancer with Endothelin Receptor Antagonists
2006
Works of Mark Weinberg being referenced
Adalimumab treatment effects on radiographic progression of joint disease in patients with psoriatic arthritis: Results from ADEPT
2005
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trial
2005
Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.
2007
Effect of Endothelin-A Receptor Blockade With Atrasentan on Tumor Progression in Men With Hormone-Refractory Prostate Cancer: A Randomized, Phase II, Placebo-Controlled Trial
2003
A new intratracheal stent made from nitinol, an alloy with “shape memory effect”
1994